Wells Fargo
RCEL icon

Wells Fargo’s Avita Medical RCEL Stock Holding History

Wells Fargo’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9K Sell
2,180
-5,104
-70% -$22K ﹤0.01% 6104
2026
Q1 		$27K Sell
7,284
-11,548
-61% -$48.5K ﹤0.01% 5673
2025
Q4 		$65K Buy
18,832
+9,345
+99% +$37.3K ﹤0.01% 5517
2025
Q3 		$48.5K Sell
9,487
-6,240
-40% -$32.6K ﹤0.01% 5554
2025
Q2 		$83.2K Buy
15,727
+1,310
+9% +$9.53K ﹤0.01% 5301
2025
Q1 		$117K Buy
14,417
+476
+3% +$4.45K ﹤0.01% 5024
2024
Q4 		$178K Buy
13,941
+4,070
+41% +$48K ﹤0.01% 4865
2024
Q3 		$106K Sell
9,871
-311
-3% -$2.92K ﹤0.01% 4990
2024
Q2 		$80.6K Buy
10,182
+660
+7% +$6.28K ﹤0.01% 5069
2024
Q1 		$153K Buy
9,522
+1,005
+12% +$16.3K ﹤0.01% 4637
2023
Q4 		$117K Buy
8,517
+1,484
+21% +$17K ﹤0.01% 4808
2023
Q3 		$103K Sell
7,033
-5,460
-44% -$92.4K ﹤0.01% 4764
2023
Q2 		$213K Buy
12,493
+10,270
+462% +$151K ﹤0.01% 4556
2023
Q1 		$31.1K Sell
2,223
-197
-8% -$2.1K ﹤0.01% 5432
2022
Q4 		$16K Sell
2,420
-746
-24% -$4.47K ﹤0.01% 5359
2022
Q3 		$17K Buy
3,166
+999
+46% +$6.17K ﹤0.01% 5487
2022
Q2 		$11K Sell
2,167
-5,614
-72% -$34.7K ﹤0.01% 5718
2022
Q1 		$66K Sell
7,781
-7,888
-50% -$72.7K ﹤0.01% 5525
2021
Q4 		$188K Buy
15,669
+14,288
+1,035% +$218K ﹤0.01% 5300
2021
Q3 		$24K Hold
1,381
– – ﹤0.01% 5911
2021
Q2 		$28K Hold
1,381
– – ﹤0.01% 5780
2021
Q1 		$27K Sell
1,381
-10,222
-88% -$238K ﹤0.01% 6066
2020
Q4 		$215K Buy
11,603
+10,971
+1,736% +$241K ﹤0.01% 5044
2020
Q3 		$16K Sell
632
-2,130
-77% -$53.1K ﹤0.01% 5809
2020
Q2 		$84K Buy
2,762
+2,257
+447% +$69K ﹤0.01% 5301
2020
Q1 		$16K Buy
505
+305
+153% +$12.6K ﹤0.01% 5652
2019
Q4 		$9K Buy
+200
New +$8.31K ﹤0.01% 5916

Other funds holding RCEL

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo's RCEL Position: Q2 2026 in Review

Wells Fargo reduced its Avita Medical (RCEL) stake by 70% in Q2 2026, selling an estimated $22K and leaving 2,180 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #6104.

Wells Fargo first reported a position in RCEL in Q4 2019 and has held it in 27 quarters since. The position peaked at $215K in Q4 2020. 73 funds tracked by Wall St. Rank hold RCEL as of Q2 2026.

  • Wells Fargo held 2,180 shares of Avita Medical worth $9K as of Q2 2026.
  • Wells Fargo sold 5,104 Avita Medical shares in Q2 2026, an estimated $22K.
  • Avita Medical made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6104 holding.
  • Wells Fargo first reported a position in Avita Medical in Q4 2019 and has held it in 27 quarters since.
  • Wells Fargo's Avita Medical position peaked at $215K in Q4 2020.
  • 73 funds tracked by Wall St. Rank held Avita Medical as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.